Maiwald Magazine

Press Coverage

25 Aug 2025 - Press Coverage

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

9 Jul 2025 - Press Coverage

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.

Maiwald in the press

Publications

10 Oct 2025 - Publication

Patentable AI applications under the EPC – from the technical perspective (English only)

Fabian Kiendl and Christian Schäflein examine how AI engineering can yield patentable inventions and consider the protection of such solutions in automotive technology under ...

2 Sep 2025 - Publication

How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025

In its ruling on EP 3 536 712 B1, the Düsseldorf Local Division of the UPC for the first time outlined crucial criteria for patent infringement based on second medical use cl...

18 Jul 2025 - Publication

EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025

In a specialist article, Kerstin Wolff analyzes the current state of EU regulation on new genomic techniques (NGTs). In February 2024, the European Parliament proposed exempti...

All publications

Events

Tue.

18 Nov 2025 |Upcoming|External Events

Maiwald is Gold Partner for the 2nd „Pharma and Biotech Patent Litigation North America“ conference

On 18 and 19 November, the second annual Pharma & Biotech Patent Litigation North America conference will take place at the Marriott Downtown in Philadelphia. Maiwald is proud to support this important event as a Gold Partner. Dr Eva Ehlich will participate in a panel discussion. The topic is how life science compani...

Tue.

18 Nov 2025 |Upcoming|Vortag Live

Joint international symposium with Oblon on November 18, 2025

The Oblon and Maiwald firms are pleased to invite you to a complimentary joint international symposium on: U.S. and European Patent Practice – Important Aspects for Practitioners Please join us to learn about recent developments an...

Wed.

5 Nov 2025 |Past Event

Maiwald at IAM Live: Navigating the UPC

On Wednesday, November 5th, the first IAM Live: Navigating the UPC conference will take place in Paris. The event offers key insights into the latest trends and cases at the Unified Patent Court (UPC), which is establishing itself as an important forum for patent disputes. Participants can learn more about the role of th...

Tue.

21 Oct 2025 |Past Event|External Events

Maiwald at IAM Live: Auto IP Europe 2025

IAM Live: Auto IP Europe 2025 is a significant trade event that unites experts from the automotive and IP sectors. The focus is on the latest challenges, trends and developments in intellectual property for the automotive industry. Participants can look forward to in-depth presentations and practical discussions on topics such as patents, design rights, technology transfer...

All events

News and Releases

Maiwald Blog

Why Patent Defense and Military Technologies?

Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

Press Coverage

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

Staff News

Dr Iris Müller and Dr Gabriel Kiefl sworn in as German patent attorneys

Marvin Bäumel sworn in as German patent attorney

Maiwald appoints Alexander Feil, Dr. Johannes Scholz and Dr. Fabian Wiescher as Counsel

Publications

Patentable AI applications under the EPC – from the technical perspective (English only)

How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025

EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025

Awards

JUVE Patent Rankings Germany 2025

Managing IP’s Rising Stars 2025

FOCUS List of Top Commercial Law Firms in Germany 2025

Events

Maiwald is Gold Partner for the 2nd „Pharma and Biotech Patent Litigation North America“ conference

Joint international symposium with Oblon on November 18, 2025

Maiwald at IAM Live: Navigating the UPC

Maiwald at IAM Live: Auto IP Europe 2025